Blackstone Inc
LXEO icon

Blackstone Inc’s Lexeo Therapeutics LXEO Stock Holding History

Blackstone Inc’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.22M Hold
904,959
– – 0.01% 125
2026
Q1 		$5.19M Hold
904,959
– – 0.02% 115
2025
Q4 		$8.99M Sell
904,959
-219,963
-20% -$2.01M 0.04% 101
2025
Q3 		$7.47M Hold
1,124,922
– – 0.03% 106
2025
Q2 		$4.52M Sell
1,124,922
-33,695
-3% -$111K 0.02% 104
2025
Q1 		$4.02M Hold
1,158,617
– – 0.02% 102
2024
Q4 		$7.62M Hold
1,158,617
– – 0.03% 84
2024
Q3 		$10.5M Buy
1,158,617
+352,860
+44% +$4.21M 0.05% 75
2024
Q2 		$12.9M Buy
805,757
+109,647
+16% +$1.59M 0.05% 72
2024
Q1 		$10.9M Hold
696,110
– – 0.04% 81
2023
Q4 		$9.34M Buy
+696,110
New +$8.65M 0.04% 71

Other funds holding LXEO

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Blackstone Inc's LXEO Position: Q2 2026 in Review

Blackstone Inc held its Lexeo Therapeutics (LXEO) position steady in Q2 2026 at 904,959 shares worth $4.22M. The position accounts for 0.01% of the portfolio, ranked #125.

Blackstone Inc first reported a position in LXEO in Q4 2023 and has held it in 11 quarters since. The position peaked at $12.9M in Q2 2024. 142 funds tracked by Wall St. Rank hold LXEO as of Q2 2026.

  • Blackstone Inc held 904,959 shares of Lexeo Therapeutics worth $4.22M as of Q2 2026.
  • Blackstone Inc left its Lexeo Therapeutics share count unchanged in Q2 2026.
  • Lexeo Therapeutics made up 0.01% of Blackstone Inc's portfolio in Q2 2026, its #125 holding.
  • Blackstone Inc first reported a position in Lexeo Therapeutics in Q4 2023 and has held it in 11 quarters since.
  • Blackstone Inc's Lexeo Therapeutics position peaked at $12.9M in Q2 2024.
  • 142 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q2 2026.

Based on Blackstone Inc's 13F filing for Q2 2026, filed 14 Aug 2026.